VIVUS Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, and VIVUS is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.
VIVUS was fortunate enough to be the first company to bring a new anti-obesity drug to market, but Qsymia hasn't been everything that investors had hoped it would be. Let's take an early look at what's been happening with VIVUS over the past quarter and what we're likely to see in its quarterly report on Monday.
Stats on VIVUS
Analyst EPS Estimate
Change From Year-Ago Revenue
Earnings Beats in Past 4 Quarters
Sources: Yahoo! Finance, S&P Capital IQ. NM = not meaningful; VIVUS had no revenue in the year-ago period.
Will VIVUS finally pay off for investors?
Analysts aren't too optimistic about VIVUS coming into its report, as they've cut nearly a dime off earnings-per-share estimates for the quarter over the past few months, and for full-year 2013, current consensus has fallen by more than $0.25 per share over the same time frame. But investors haven't been deterred by those concerns, as the stock is up more than 25% since mid-November.
VIVUS wasn't the first company to get its obesity drug approved, as Arena Pharmaceuticals managed to get its Belviq drug past the FDA gates first. But Arena hasn't been able to release Belviq pending DEA classification, VIVUS got a head start on sales. After a slow start, sales have picked up somewhat, with the company saying that sales in the late November to late December period rose 68% from the prior four-week period.
More recently, though, questions have arisen about whether any blockbuster anti-obesity drug will emerge from the fray. Safety issues have again come up, with the regulatory agency responsible for approving drugs in the European Union rejecting VIVUS's appeal pending more clinical data on potential risks of cardiovascular problems. Moreover, even if safety concerns with anti-obesity drugs get resolved successfully, most medications can't solve obesity without accompanying changes in patient behavior.
Moreover, cost has been a concern, as 30% of patients have given up their prescriptions. Aetna changed its policies to call Qsymia and Belviq "medically necessary" and therefore allowed them to qualify for drug benefits in many cases, and pharmacy benefits manager Express Scripts has added Qsymia to its national formulary, opening the door to copayments of $50 to $60 for many patients. Other insurance providers may conclude that encouraging obesity treatment leads to lower overall health costs in the long run and therefore make the same change.
In VIVUS' coming report, the big number to look for is full-quarter sales of Qsymia. If the company can draw new patients in and keep existing customers on the drug, then VIVUS will have set itself up as well as possible for the inevitable release of Belviq -- which will change the game entirely both for VIVUS and Arena.
Is now the time to sell VIVUS?
Qsymia hasn't had the best start, but does that mean that investors should give up on VIVUS right now? Find out what our top pharma expert thinks about VIVUS' future prospects by reading his premium research report on the company. It includes a detailed look at both sides of the Qsymia argument and comes with a full year of free updates. Don't wait; click here now and get started with your report.
Click here to add VIVUS to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
The article VIVUS Earnings: An Early Look originally appeared on Fool.com.Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.